Jiangsu Sihuan Bioengineering Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2019
October 30, 2019 at 03:49 am
Share
Jiangsu Sihuan Bioengineering Co. Ltd. announced earnings results for the nine months ended September 30, 2019. For the nine months, the company announced sales was CNY 0 compared to CNY 281.411 million a year ago. Sales was CNY 285.787 million compared to CNY 0 a year ago. Sales was CNY 285.787 million compared to CNY 281.411 million a year ago. Operating income was CNY 15.698 million compared to operating loss of CNY 6.607 million a year ago. Net income was CNY 9.478 million compared to net loss of CNY 9.392 million a year ago. Basic earnings per share from continuing operations was CNY 0.0092 compared to basic loss per share from continuing operations of CNY 0.0091 a year ago.
JIANGSU SIHUAN BIOENGINEERING CO., LTD is a China-based company principally engaged in the research, development, manufacture and distribution of medicines and health supplements. The Companyâs main products include interleukin, erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF), tablets, bulk drugs, infusion glass bottles, soft bag infusion, syrup and healthcare products, among others. The Company is also engaged in landscape engineering, maintenance projects, the sale of nursery stocks and other businesses. The Company distributes its products in domestic market and to overseas markets.
JIANGSU SIHUAN BIOENGINEERING CO., LTD 
